LNTH Lantheus Holdings Inc

Lantheus to Host Fourth Quarter and Full Year 2024 Earnings Conference Call and Webcast on February 26, 2025, at 8:00 a.m. Eastern Time

Lantheus to Host Fourth Quarter and Full Year 2024 Earnings Conference Call and Webcast on February 26, 2025, at 8:00 a.m. Eastern Time

BEDFORD, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, February 26, 2025, to discuss its financial and operating results for the fourth quarter and full year of 2024.

To access the conference call or webcast, participants should register online at . To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time.

A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least 30 days.

About Lantheus

Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years. For more information, visit .

Contacts:

Mark Kinarney

Vice President, Investor Relations

978-671-8842



Melissa Downs

Senior Director, External Communications

646-975-2533



EN
12/02/2025

Underlying

LNTHLantheus Holdings Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lantheus Holdings Inc

 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus Completes Acquisition of Evergreen Theragnostics

Lantheus Completes Acquisition of Evergreen Theragnostics BEDFORD, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that it has completed its previously announced acquisition of Evergreen Theragnostics, Inc. (“Evergreen”), a clinical-stage radiopharmaceutical company. The acquisition was first announced on January 28, 2025. Through the transaction, Lantheus has ...

April 1, 2025 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus Reports Fourth Quarter and Full Year 2024 Financial Performan...

Lantheus Reports Fourth Quarter and Full Year 2024 Financial Performance Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024Free cash flow was $141.4 million and $493.1 million for the fourth quarter and full year 2024GAAP fully diluted loss per share of $(0.17) and earnings per share of $4.36 for the fourth quarter and full year 2024Adjusted fully diluted earnings per share of $1.59 and $6.76 for the fourth quarter and full year 2024PYLARIFY exceeds $1 billion in net sales and becomes first ever blockbuster radiodiagnosticCompany announces a seri...

February 26, 2025 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus to Present at Upcoming Investor Conferences

Lantheus to Present at Upcoming Investor Conferences BEDFORD, Mass., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced members of its management team will present at the following upcoming investor conferences. B. Riley Securities Precision Oncology & Radiopharma Day in New York on February 28TD Cowen 45th Annual Health Care Conference in Boston on March 4 at 2:30 pm ETLeerink Global Hea...

February 21, 2025 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus to Host Fourth Quarter and Full Year 2024 Earnings Conference...

Lantheus to Host Fourth Quarter and Full Year 2024 Earnings Conference Call and Webcast on February 26, 2025, at 8:00 a.m. Eastern Time BEDFORD, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, February 26, 2025, to discuss its financial and operating results for the fourth quarter and full year of 2024. To access the conference call or webcast, participants should register online at . To avoid delays, we encourage participants to register fifteen minutes ahead of the sch...

February 12, 2025 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus Announces Presentations Featuring PYLARIFY (Piflufolastat F 1...

Lantheus Announces Presentations Featuring PYLARIFY (Piflufolastat F 18) Data at the ASCO GU Meeting Data highlights PYLARIFY’s ability to detect recurrent prostate cancer in patients with low PSA Real-world evidence of PYLARIFY’s effectiveness in prostate cancer being presented BEDFORD, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced pifl...

February 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch